These databases contain large cohorts of > 2600 BC patients that were classified by PAM50 as the BLBC/TNBC, luminal-A and luminal-B, Her2+, and normal-like BC subtypes, and the information about mRNA expression, mutations, copy-number variations, and associated clinical/pathological data (stages/grades and relapse status). This evidence concerns the gene ERBB2 and breast cancer.